5-chloro-2-propylphenylamine | 90415-69-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-2-propylphenylamine
• 英文别名: 3-chloro-6-propylaniline；2-Propyl-5-chlor-anilin；5-Chloro-2-propylaniline
• CAS: 90415-69-3
• 化学式: C₉H₁₂ClN
• 分子量: 169.654
• InChiKey: WLDQMSFTOOEUBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-chloro-2-propylphenylamine 在 吡啶 作用下， 生成 (5-氯-2-丙基苯基)4-溴苯磺酸盐
  参考文献：
  名称：

  The ortho-Claisen Rearrangement. V. The Products of Rearrangement of Allyl m-X-Phenyl Ethers¹

  摘要：

  DOI：

  10.1021/jo01068a004
• 作为产物：
  描述：

  2-Propyl-5-chlor-1-nitro-benzol 在 盐酸 、 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 生成 5-chloro-2-propylphenylamine
  参考文献：
  名称：

  The ortho-Claisen Rearrangement. V. The Products of Rearrangement of Allyl m-X-Phenyl Ethers¹

  摘要：

  DOI：

  10.1021/jo01068a004

文献信息

• [EN] PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA<br/>[FR] DERIVES DE PYRROLYDIN-2-ONE UTILISES COMME INHIBITEURS DE LA THROMBINE ET DU FACTEUR XA
  申请人：GLAXO GROUP LTD

  公开号：WO2004052851A1

  公开（公告）日：2004-06-24

  The invention relates to compounds of formula (I), wherein : R1 represents hydrogen, C1-4 alkyl, -CH2CO2H, -CH2CO2C1-2alkyl, or -CH2CONR7R8; R2 and R3 independently represent hydrogen, -C1-6alkyl, -C1-3alkylCN, -C1-3alkylCO2H, -C1-4alkylOC1-4alkyl, -C1-4alkylS(O)nC1-4alkyl, -C1-4alkylNR10R11, -C1-3alkylNCO2C1-4alkyl, -C1-3alkylCONR7R8, -C1-3alkylCO2C0-2alkylR9, -C1-3alkylCOC0-2alkylR9, -C1-3alkylCON(R8) C0-2 alkylR9, -C1-3alkylNCO2C0-2alkylR9, -C1-3alkylNCOC0-2alkylR9 or -C0-2alkylR9, with the proviso that one of R2 and R3 is hydrogen and the other is a substituent other than hydrogen; n is an integer between 0 and 2; R4 and R5 together with the nitrogen atom to which they are attached form a morpholino ring; R6 represents a group selected from formula (II) wherein T1 and T2 independently represent CH2, NH, S or O with the proviso that when one of T1 or T2 represents NH, S or O the other represents CH2; M represents CH3, -OH or PO; V represents CH or N; W represents H, CH3, Cl or F; X represents C1, Br, F or -CH3; Y represents CH3 or CF3; Z represents -CH3 or F; R7 and R8 are independently hydrogen, C1-4alkyl or together with the N atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from O, N or S; R10 and R11 independently represent C1-4alkyl or together with the N atom towhich they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additionalheteroatom selected from O, N or S; R9 represents phenyl or a 5- or 6- membered aromatic or non-aromatic heterocyclic group, containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: C1-3alkyl or halogen; and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated.

  该发明涉及式(I)的化合物，其中：R1代表氢，C1-4烷基，- CO2H，- CO2C1-2烷基，或- CONR7R8；R2和R3独立地代表氢，-C1-6烷基，-C1-3烷基CN，-C1-3烷基CO2H，-C1-4烷基OC1-4烷基，-C1-4烷基S(O)nC1-4烷基，-C1-4烷基NR10R11，-C1-3烷基NCO2C1-4烷基，-C1-3烷基CONR7R8，-C1-3烷基CO2C0-2烷基R9，-C1-3烷基COC0-2烷基R9，-C1-3烷基CON(R8) C0-2烷基R9，-C1-3烷基NCO2C0-2烷基R9，-C1-3烷基NCOC0-2烷基R9或-C0-2烷基R9，但要求R2和R3中的一个为氢，另一个为非氢取代基；n是0到2之间的整数；R4和R5与它们连接的氮原子一起形成吗啡环；R6代表从式(II)中选择的基团，其中T1和T2独立地代表CH2，NH，S或O，但要求当T1或T2代表NH，S或O时，另一个代表 ；M代表CH3，-OH或PO；V代表CH或N；W代表H， ，Cl或F；X代表C1，Br，F或- ；Y代表 或CF3；Z代表- 或F；R7和R8独立地代表氢，C1-4烷基，或者与它们连接的N原子一起形成一个5-或6-成员非芳香杂环，选择性地包含另一个从O，N或S中选择的杂原子；R10和R11独立地代表C1-4烷基，或者与它们连接的N原子一起形成一个5-或6-成员非芳香杂环，选择性地包含另一个从O，N或S中选择的杂原子；R9代表苯基或一个5-或6-成员芳香或非芳香杂环基团，其中至少含有一个从O，N或S中选择的杂原子，每个基团选择性地被0-2个从C1-3烷基或卤素中选择的基团取代；以及其药用可接受的衍生物，其制备方法，含有它们的药物组合物以及在医学中的使用，特别是在改善需要凝血酶抑制剂的临床状况中的使用。
• METHOD FOR PRODUCING BIARYL COMPOUND
  申请人：Sato Koichi

  公开号：US20100087680A1

  公开（公告）日：2010-04-08

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种制备双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱的存在下，将芳香有机化合物与选自芳香基有机硼化合物和硼氧化物化合物组的至少一种化合物反应。
• QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160272595A1

  公开（公告）日：2016-09-22

  The present invention relates to quinazolinone and isoquinolinone derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

  本发明涉及由式(I)所表示的喹唑啉酮和异喹唑啉酮衍生物或其药学上可接受的盐。
• PROCESS FOR PRODUCING BIARYL COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1914221A1

  公开（公告）日：2008-04-23

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种生产双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱存在下，使芳香族有机化合物与至少一种选自由芳香族有机硼化合物和硼氧化合物组成的组中的化合物反应。
• Antipruritics
  申请人：SHIONOGI & CO., LTD.

  公开号：EP2130820A1

  公开（公告）日：2009-12-09

  The present invention relates to the use of a compound having an agonistic activity to the cannabinoid receptor, a prodrug, a pharmaceutically acceptable salt or solvate thereof for the preparation of an antipruritic, wherein the compound having an agonistic activity to the cannabinoid receptor is a compound selected from (R,S)-4,4,4-trifluoro-1-butane sulfonic acid-3-(2-hydroxymethyl-indanyl-4-oxy)-phenylester; (S)-1-(4,4,4-trifluoro-1-butane sulfonic acid-3-(2-hydroxymethyl-indanyl-4-oxy)phenyl ester; and (R)-1-(4,4,4-trifluoro-1-butane sulfonic acid-3-(2-hydroxymethyl-indanyl-4-oxy)phenyl ester.

  本发明涉及一种对大麻素受体具有激动活性的化合物、其原药、药学上可接受的盐或溶液用于制备止痒剂的用途，其中对大麻素受体具有激动活性的化合物是选自以下各项的化合物 (R,S)-4,4,4-三氟-1-丁烷磺酸-3-(2-羟甲基-茚满-4-氧基)-苯酯； (S)-1-(4,4,4-三氟-1-丁烷磺酸-3-(2-羟甲基-茚满-4-氧基)苯基酯；和 (R)-1-(4,4,4-三氟-1-丁烷磺酸-3-(2-羟甲基-茚满-4-氧基)苯基酯。